000056058 001__ 56058
000056058 005__ 20221006113637.0
000056058 0247_ $$2doi$$a10.1093/ijnp/pyv121
000056058 0248_ $$2sideral$$a94921
000056058 037__ $$aART-2016-94921
000056058 041__ $$aeng
000056058 100__ $$aBioque, M.
000056058 245__ $$aA pharmacovigilance study in first episode of psychosis: Psychopharmacological interventions and safety profiles in the peps project
000056058 260__ $$c2016
000056058 5060_ $$aAccess copy available to the general public$$fUnrestricted
000056058 5203_ $$aBackground: The characterization of the first episode of psychosis and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of psychosis attended in daily practice. Methods: Sixteen participating centers from the PEPs project recruited 335 first episode of psychosis patients, aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. Results: The majority of first episode of psychosis patients received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight patients were taking clozapine, all in monotherapy. Males received higher doses of antipsychotic (P=.043). A total of 5.2% of the patients were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received benzodiazepines; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P<.001). Conclusions: These data indicate that the overall pharmacologic prescription for treating a first episode of psychosis in Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of psychosis, such as the role of clozapine, long-acting injectable antipsychotics, antipsychotic combination, and the use of benzodiazepines.
000056058 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI08-0208
000056058 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000056058 590__ $$a4.712$$b2016
000056058 591__ $$aCLINICAL NEUROLOGY$$b28 / 194 = 0.144$$c2016$$dQ1$$eT1
000056058 591__ $$aPSYCHOLOGY, EXPERIMENTAL$$b23 / 142 = 0.162$$c2016$$dQ1$$eT1
000056058 591__ $$aPHARMACOLOGY & PHARMACY$$b29 / 256 = 0.113$$c2016$$dQ1$$eT1
000056058 591__ $$aNEUROSCIENCES$$b51 / 258 = 0.198$$c2016$$dQ1$$eT1
000056058 592__ $$a1.997$$b2016
000056058 593__ $$aPharmacology$$c2016$$dQ1
000056058 593__ $$aPsychiatry and Mental Health$$c2016$$dQ1
000056058 593__ $$aPharmacology (medical)$$c2016$$dQ1
000056058 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000056058 700__ $$aLlerena, A.
000056058 700__ $$aCabrera, B.
000056058 700__ $$aMezquida, G.
000056058 700__ $$0(orcid)0000-0002-9098-655X$$aLobo, A.$$uUniversidad de Zaragoza
000056058 700__ $$aGonzález-Pinto, A.
000056058 700__ $$aDíaz-Caneja, C.M.
000056058 700__ $$aCorripio, I.
000056058 700__ $$aAguilar, E.J.
000056058 700__ $$aBulbena, A.
000056058 700__ $$aCastro-Fornieles, J.
000056058 700__ $$aVieta, E.
000056058 700__ $$aLafuente, A.
000056058 700__ $$aMas, S.
000056058 700__ $$aParellada, M.
000056058 700__ $$aSaiz-Ruiz, J.
000056058 700__ $$aCuesta, M.J.
000056058 700__ $$aBernardo, M.
000056058 700__ $$aGassó, P.
000056058 700__ $$aAmoretti, S.
000056058 700__ $$aGarcía Bernardo, E.
000056058 700__ $$aTapia-Casellas, C.
000056058 700__ $$aAlonso-Solís, A.
000056058 700__ $$aGrasa, E.
000056058 700__ $$aHernández, M.
000056058 700__ $$aGonzález, I.
000056058 700__ $$aRuiz, P.
000056058 700__ $$aModrego, F.
000056058 700__ $$aEscartí, M.J.
000056058 700__ $$aMané, A.
000056058 700__ $$aTorrent, C.
000056058 700__ $$aBaeza, I.
000056058 700__ $$aContreras, F.
000056058 700__ $$aAlbacete, A.
000056058 700__ $$aBobes, J.
000056058 700__ $$aGarcía-Portilla, Ma P.
000056058 700__ $$aZabala Rabadán, A.
000056058 700__ $$aSegarra Echevarría, R.
000056058 700__ $$aRodriguez-Jimenez, R.
000056058 700__ $$aMorales-Muñoz, I.
000056058 700__ $$aButjosa, A.
000056058 700__ $$aLandin-Romero, R.
000056058 700__ $$aSarró, S.
000056058 700__ $$aIbáñez, Á.
000056058 700__ $$aSánchez-Torres, A.Ma
000056058 700__ $$aBalanzá-Martínez, V.
000056058 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000056058 773__ $$g19, 4 (2016), 1-10$$pInt. j. neuropsychopharmacol.$$tINTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY$$x1461-1457
000056058 8564_ $$s674268$$uhttps://zaguan.unizar.es/record/56058/files/texto_completo.pdf$$yVersión publicada
000056058 8564_ $$s117695$$uhttps://zaguan.unizar.es/record/56058/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000056058 909CO $$ooai:zaguan.unizar.es:56058$$particulos$$pdriver
000056058 951__ $$a2022-10-06-11:32:06
000056058 980__ $$aARTICLE